Lobe Sciences EBIT

The latest EBIT for LOBEF is $-6.8M as of May 2026. That compares with $-4.9M in the prior-year period — down 39.9% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Lobe Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, LOBEF's EBIT moved from $-4.9M to $-6.8M — a 39.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lobe Sciences's operating scale or balance-sheet position.

Against Healthcare companies, LOBEF currently prints $-6.8M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Lobe Sciences's growth, margins, and balance sheet.

A EBIT figure of $-6.8M for LOBEF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting LOBEF's EBIT ($-6.8M), review year-over-year change from $-4.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.